⌕
Novo Nordisk · NVO · NYSE
Tenet 62 · Solid
Compare
$40.70−2.16%At closeTenet 62 · Solid
$40.70−0.90 (−2.16%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$40.12−0.58 (−1.43%)
After hours: Nov 17, 2026, 7:57 PM ET

Novo Nordisk (NVO) Stock Checks

How NVO measures up against value, income, timing, and long-hold tenets. Every criterion shows the number as of the last close and the pass rule. Always free.

Sources Company filings and computed by Tenet Filings and TenetScreens as of How we compute thisNot investment advice

The tenets below and the 0-100 Tenet Score on this report are two separate computations: each tenet runs its own criteria and its own pass rule, while the score is a percentile composite reported as one of four verdict words (Strong, Solid, Mixed or Weak).

3 / 17 qualify todayas of close, Nov 16, 2026 · computed nightly from our fundamentals DB; point-in-time auditable.
QUALIFIES
3
meet every gate today
BORDERLINE
6
within one input of the gate
FAILS
6
miss at least one gate
UNKNOWN
2
insufficient data to judge
Buffett Qualitydurable moat
✓ Qualifies
PassesROE ≥ 15%63.9% · ≥ 15.0%
PassesGross margin ≥ 40%81.0% · ≥ 40.0%
PassesNet margin ≥ 15%33.1% · ≥ 15.0%
FailsDebt/equity ≤ 0.50.69 · ≤ 0.50
PassesGrowing FCF (multi-yr)14.8% · > 0
Decided by the pass rule for Buffett Quality.
The badge above reads a pass with 1 of the checks below marked as failing. The pass rule for Buffett Quality is what decides that verdict, and it is not restated here.Buffett Quality under The screens ›Today's Buffett Quality list ›
PassesReturn on assets positive18.9% · > 0
PassesOperating cash flow positive$21.1B · > 0
FailsReturn on assets improving21.7% → 18.9%
PassesEarnings backed by cash (CFO > net income)$21.1B vs $16.1B
FailsLeverage falling (long-term debt / assets)19.3% → 21.9%
PassesCurrent ratio improving0.74 → 0.80
PassesNo share dilution (≤ +2%)+0.0%
FailsGross margin expanding84.7% → 81.0%
FailsAsset turnover improving0.62 → 0.57
Decided by the pass rule for Piotroski F-Score.
The pass rule for Piotroski F-Score is what decides that verdict, and it is not restated here.Piotroski F-Score under The screens ›Today's Piotroski F-Score list ›
PassesROIC ≥ 15%30.6% · ≥ 15.0%
Unknown — no dataNet debt/EBITDA ≤ 3×— · ≤ 3.0×
PassesAltman Z ≥ 3 (safe zone)3.79 · ≥ 3.00
Decided by the pass rule for Munger Compounders.
The pass rule for Munger Compounders is what decides that verdict, and it is not restated here. 1 of 3 carry no data.Munger Compounders under The screens ›Today's Munger Compounders list ›
PassesEBIT > 0$20.1B · > 0
Unknown — no dataEarnings yield EBIT/EV ≥ 6%— · ≥ 6.0%
Unknown — no dataReturn on capital ≥ 25%— · ≥ 25.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 3 checks below carry data. The pass rule for Magic Formula is not published separately on the methodology page.About this screen ›Today's Magic Formula® list ›
PassesSize: market cap ≥ $2B$185.7B · ≥ $2.0B
FailsCurrent ratio ≥ 20.80 · ≥ 2.00
PassesPositive EPS 7y7y
PassesPays a dividend$1.16 · > 0
Unknown — no dataEPS growth ≥ 3%/yr— · ≥ 3.0%
PassesP/E ≤ 1511.54 · ≤ 15.00
FailsP/E × P/B ≤ 22.570.30 · ≤ 22.50
Decided by the pass rule for Graham Defensive.
The pass rule for Graham Defensive is what decides that verdict, and it is not restated here. 1 of 7 carry no data.Graham Defensive under The screens ›Today's Graham Defensive list ›
Unknown — no dataPEG < 1 (hist. growth)— · < 1.00
Unknown — no dataEPS growth 10–30%— · 10.0%–30.0%
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 2 checks below carry data.Lynch GARP under The screens ›Today's Lynch GARP list ›
PassesPays a dividend$1.16 · > 0
PassesYield in a healthy band (not a yield trap)2.8% · 1.0%–8.0%
PassesCovered by free cash flow1.44 · ≥ 1.20
PassesEarnings payout not stretched50.5% · ≤ 75.0%
Unknown — no dataBalance sheet can sustain the payout— · ≤ 4.0×
FailsAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)6.00 · ≥ 10.00
FailsNo dividend cut in the last 5 yearsLast cut 2023
Passes5-year dividend growth ≥ 5%/yr17.7% · ≥ 5.0%
Decided by the pass rule for Income & Dividend Safety.
The pass rule for Income & Dividend Safety is what decides that verdict, and it is not published separately on the methodology page. 1 of 8 carry no data.
PassesPays a dividend$1.16 · > 0
FailsAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)6.00 · ≥ 10.00
FailsNo dividend cut in the last 5 yearsLast cut 2023
Passes5-year dividend growth ≥ 5%/yr17.7% · ≥ 5.0%
PassesCovered by free cash flow1.44 · ≥ 1.20
PassesPayout not stretched50.5% · ≤ 75.0%
Decided by the pass rule for Dividend Growth.
The pass rule for Dividend Growth is what decides that verdict, and it is not restated here.Dividend Growth under The screens ›Today's Dividend Growth list ›
PassesReturn on invested capital ≥ 15% in 4+ of the last 5 years5 of 5
PassesRevenue compounding ≥ 8%/yr over 5 years18.4% · ≥ 8.0%
FailsNot diluting: diluted share count flat-to-down (≤ +1%/yr)17.9% · ≤ 1.0%
PassesFree cash flow margin ≥ 12%24.1% · ≥ 12.0%
PassesEarnings backed by cash (operating cash flow ≥ net income)1.31 · ≥ 1.00
Reading: does not hold. Not a gate checkDisciplined buybacks: actively reducing the share count (bonus)reading, not a gate check17.9%
Decided by the pass rule for Quality Compounder.
The pass rule for Quality Compounder is what decides that verdict, and it is not restated here. Lines marked as readings are published beside the checks and are not gate checks.Quality Compounder under The screens ›Today's Quality Compounder list ›
FailsOff its 52-week high by 8–35% (a dip, not a collapse)35.2% · 8.0%–35.0%
FailsDip within its own normal pullback band0.24
FailsNot past where its dips have historically recovered from1.61
FailsA dip in an uptrend (above a rising 200-day)43.09
FailsHigher-low structure still intactstructure broken · no higher low
Unknown — no dataClear of the earnings blackout (more than 5 days out)— · > 5.00
Decided by the pass rule for Drawdown Context.
The pass rule for Drawdown Context is what decides that verdict, and it is not published separately on the methodology page. 1 of 6 carry no data.
Unknown — no dataA bullish MACD cross within 10 sessions— · ≤ 10.00
PassesReclaimed a rising 50-day EMA40.87
FailsPrinted a higher lowno
FailsA volume thrust on the turn (≥ 1.2× normal)1.05 · ≥ 1.20
FailsReversal signals fired: 3 of 4 (MACD·MA·HL·Vol)1.00 · ≥ 3.00
Decided by the pass rule for Reversal Evidence.
The pass rule for Reversal Evidence is what decides that verdict, and it is not published separately on the methodology page. 1 of 5 carry no data.
PassesIn the cheap half of its own 5-year valuation range0.2×
PassesEarnings estimates not being cut0.05
FailsReturns on capital not deteriorating0.31
Decided by the pass rule for Not-a-Value-Trap Gate.
The pass rule for Not-a-Value-Trap Gate is what decides that verdict, and it is not published separately on the methodology page.
PassesOperating profit is positive$20.1B · > 0
PassesReturn on invested capital ≥ 10%30.6% · ≥ 10.0%
Not scored: see the reason belowA solvent balance sheet (Altman Z ≥ 1.8, net debt/EBITDA ≤ 4)We hold no net-debt figure for this company, so only the Altman Z half of this two-part test (the number shown beside this line) could be measured. It is left unscored rather than counted either way.3.8×
PassesQuality score ≥ 5070.90 · ≥ 50.00
PassesRevenue growing over 5 years18.4% · > 0
Decided by the pass rule for Quality Floor.
The pass rule for Quality Floor is what decides that verdict, and it is not published separately on the methodology page. 1 of 5 carry no data.
A research signal from published criteria, not a recommendation.
FailsDrawdown context35.2% off its 52-week high
FailsReversal evidence1 of 4 signals fired
FailsTrap gate2 of 3 held
PassesQuality floor4 of 5 held · 1 no data
Invalidation level (structure break): below this the dip's structure has broken$44.28
Decided by the pass rule for Qualified Dip.
The pass rule for Qualified Dip is what decides that verdict, and it is not restated here.Qualified Dip under The screens ›Today's Qualified Dip list ›
PassesTrading above its 50-day average39.99
FailsTrading above its 200-day average43.09
Fails50-day average above the 200-day (uptrend stack)39.99
Fails50-day average sloping up−0.06 · > 0
Decided by the pass rule for Trend Alignment.
The pass rule for Trend Alignment is what decides that verdict, and it is not published separately on the methodology page.
Fails3-month return in the top half of the universe0.40 · ≥ 0.50
Fails12-minus-1 momentum in the top half of the universe0.16 · ≥ 0.50
FailsRelative strength vs the S&P 500 improving−0.00 · > 0
PassesEarnings estimates being revised up0.05
Decided by the pass rule for Relative Strength.
The pass rule for Relative Strength is what decides that verdict, and it is not published separately on the methodology page.
PassesMACD above its signal line0.44
Not scored: see the reason belowBack above the 50-day on a fresh cross (≤10 sessions)This is a two-part reading (price back above the 50-day, and a bullish momentum cross inside 10 sessions) and a dated momentum cross is not on record for this name yet, so it is left unscored rather than counted either way.—
FailsHigher high and higher low (stair-stepping up)no higher high · no higher low
FailsA volume thrust on the move (≥ 1.2× normal)1.05 · ≥ 1.20
Decided by the pass rule for Momentum Trigger.
The pass rule for Momentum Trigger is what decides that verdict, and it is not published separately on the methodology page. 1 of 4 carry no data.
Average daily swing: normal0.03
Volatility band width: mid-range0.26
Distance from its 52-week high: a deep pullback0.35
Every verdict is auditableEach criterion shows the number as of the last close and the pass rule side by side: a receipt, not a rating. Several of these screens publish their rule in full under The screens; each row links to its own section where there is one.
Unknown ≠ failAn “— Unknown” verdict means the inputs were insufficient: context, not a signal, and never counted as a fail.

How many investing rule sets does Novo Nordisk pass?

Novo Nordisk qualifies on 3 of 17 rule sets as of 2026-11-16, with 6 borderline and 6 failing.

Does Novo Nordisk meet the Graham Defensive criteria?

Novo Nordisk is borderline on the Graham Defensive rule set as of 2026-11-16.

Does Novo Nordisk meet the Buffett Quality criteria?

Novo Nordisk qualifies on the Buffett Quality rule set as of 2026-11-16.

Computed from our fundamentals DB; historical-CAGR PEG basis for Lynch. Research, not investment advice. Tenet's rulesets are independently developed from publicly available sources, and Tenet is not affiliated with, sponsored by, endorsed by or otherwise associated with any referenced investor or trademark owner. Full notice. MAGIC FORMULA is a trademark of MagicFormulaInvesting.com LLC.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.